Skip to main content
Erschienen in:

11.01.2024 | ORIGINALIEN

Interstitielle Lungenerkrankung bei rheumatischen Erkrankungen

verfasst von: Dr. Michael Grohs

Erschienen in: rheuma plus | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Interstitielle Lungenerkrankungen (ILD) stellen eine heterogene Gruppe von pulmonalen Pathologien dar, die durch entzündliche und fibrotische Veränderungen im interstitiellen Gewebe der Lunge gekennzeichnet sind. Diese Erkrankungen können in Verbindung mit verschiedenen rheumatischen Erkrankungen auftreten, wodurch ihre Komplexität und klinische Bedeutung erhöht werden. Da eine Lungenbeteiligung zu erhöhter Morbidität und Mortalität führt, ist das frühzeitige Erkennen einer solchen von enormer Bedeutung. Eine sorgfältige Anamnese und klinische Untersuchung sowie das Antikörperprofil und ggf. Screeningmaßnahmen sollen helfen, diese wichtige Komplikation frühzeitig zu erkennen, um rasch eine mögliche Therapieänderung einzuleiten oder engmaschigere Kontrollen zu veranlassen. Aufgrund der erweiterten Therapielandschaft stehen wirksame antientzündliche und antifibrotische Therapien zur Verfügung.
Literatur
1.
Zurück zum Zitat Best AC et al (2008) Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 246(3):935–940CrossRefPubMed Best AC et al (2008) Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 246(3):935–940CrossRefPubMed
2.
Zurück zum Zitat Chatterjee S et al (2023) Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease. Baillieres Clin Rheumatol 42(3):653–661CrossRef Chatterjee S et al (2023) Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease. Baillieres Clin Rheumatol 42(3):653–661CrossRef
3.
4.
Zurück zum Zitat Chung JH, Walker CM, Hobbs S (2020a) Imaging features of systemic sclerosis-associated interstitial lung disease. J Vis Exp (160) Chung JH, Walker CM, Hobbs S (2020a) Imaging features of systemic sclerosis-associated interstitial lung disease. J Vis Exp (160)
5.
Zurück zum Zitat Chung JH, Walker CM, Hobbs S (2020b) Imaging features of systemic sclerosis-associated interstitial lung disease. J Vis Exp (160) Chung JH, Walker CM, Hobbs S (2020b) Imaging features of systemic sclerosis-associated interstitial lung disease. J Vis Exp (160)
6.
Zurück zum Zitat Dawson JK et al (2021) Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol Int 41(6):1055–1064CrossRefPubMedPubMedCentral Dawson JK et al (2021) Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol Int 41(6):1055–1064CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Distler O et al (2019) Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 380(26):2518–2528CrossRefPubMed Distler O et al (2019) Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 380(26):2518–2528CrossRefPubMed
9.
Zurück zum Zitat Fernández-Díaz C et al (2021) Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 caucasian patients. Rheumatology 61(1):299–308CrossRefPubMed Fernández-Díaz C et al (2021) Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 caucasian patients. Rheumatology 61(1):299–308CrossRefPubMed
10.
Zurück zum Zitat Flaherty KR et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381(18):1718–1727CrossRefPubMed Flaherty KR et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381(18):1718–1727CrossRefPubMed
11.
Zurück zum Zitat Grohs M et al (2022) Value of CT and transthoracic lung ultrasound in patients with systemic sclerosis : joint statement of the ÖRG/ÖGP/ÖGR/ÖGUM. Z Rheumatol 81(7):610–618CrossRefPubMedPubMedCentral Grohs M et al (2022) Value of CT and transthoracic lung ultrasound in patients with systemic sclerosis : joint statement of the ÖRG/ÖGP/ÖGR/ÖGUM. Z Rheumatol 81(7):610–618CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hyldgaard C et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76(10):1700–1706CrossRefPubMed Hyldgaard C et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76(10):1700–1706CrossRefPubMed
13.
Zurück zum Zitat Ibfelt EH et al (2021) Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology 60(1):346–352CrossRefPubMed Ibfelt EH et al (2021) Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology 60(1):346–352CrossRefPubMed
14.
Zurück zum Zitat Joy GM et al (2023) Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev 32(167):220210CrossRefPubMedPubMedCentral Joy GM et al (2023) Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev 32(167):220210CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Khanna D et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963–974CrossRefPubMed Khanna D et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963–974CrossRefPubMed
16.
Zurück zum Zitat Koo S‑M, Uh S‑T (2017) Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view. Korean J Intern Med 32(4):600–610CrossRefPubMedPubMedCentral Koo S‑M, Uh S‑T (2017) Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view. Korean J Intern Med 32(4):600–610CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Moazedi-Fuerst FC et al (2015) Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol 33(4 Suppl 91):S87–S91PubMed Moazedi-Fuerst FC et al (2015) Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol 33(4 Suppl 91):S87–S91PubMed
19.
20.
21.
Zurück zum Zitat Eroglu SD et al (2022) Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 39(3):e2022029 Eroglu SD et al (2022) Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 39(3):e2022029
23.
Zurück zum Zitat Tashkin DP et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666CrossRefPubMed Tashkin DP et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666CrossRefPubMed
24.
Zurück zum Zitat Tashkin DP et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719CrossRefPubMedPubMedCentral Tashkin DP et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Tseng C‑C et al (2023) The role of macrophages in connective tissue disease-associated interstitial lung disease: focusing on molecular mechanisms and potential treatment strategies. Int J Mol Sci 24(15) Tseng C‑C et al (2023) The role of macrophages in connective tissue disease-associated interstitial lung disease: focusing on molecular mechanisms and potential treatment strategies. Int J Mol Sci 24(15)
26.
Zurück zum Zitat Wang Y et al (2021) The role of lung ultrasound B‑lines and serum KL‑6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Res Ther 23(1):212CrossRefPubMedPubMedCentral Wang Y et al (2021) The role of lung ultrasound B‑lines and serum KL‑6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Res Ther 23(1):212CrossRefPubMedPubMedCentral
Metadaten
Titel
Interstitielle Lungenerkrankung bei rheumatischen Erkrankungen
verfasst von
Dr. Michael Grohs
Publikationsdatum
11.01.2024
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 3/2024
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-023-00692-x